Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes

References

• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. doi:10.1056/NEJMra1406184
   PubMed Web of Science ®Google Scholar
• Badar T, Patel KP, Thompson PA, et al. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. 2015;39(12):1367–1374. doi:10.1016/j.leukres.2015.10.005
   PubMed Web of Science ®Google Scholar
• Badar T, Szabo A, Sallman D, et al. Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leuk Lymphoma. 2020;61(6):1418–1427. doi:10.1080/10428194.2020.1719089
   PubMed Web of Science ®Google Scholar
• Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020;10(10):107. doi:10.1038/s41408-020-00376-1
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41. doi:10.1038/s41408-021-00425-3
   PubMed Web of Science ®Google Scholar
• Badar T, Ravandi F. Relapsed acute myeloid leukemia: need for innovative treatment strategies to improve outcome. Clin Lymphoma Myeloma Leuk. 2015;15:S104–S108. doi:10.1016/j.clml.2015.03.012
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Wang R, Wang X, et al. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv. 2020;4(10):2192–2201. doi:10.1182/bloodadvances.2020001779
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021;22(11):1597–1608. doi:10.1016/S1470-2045(21)00494-0
   PubMed Web of Science ®Google Scholar
• Andreozzi F, Massaro F, Wittnebel S, Spilleboudt C, Lewalle P, Salaroli A. New perspectives in treating acute myeloid leukemia: driving towards a patient-tailored strategy. Int J Mol Sci. 2022;23:7. doi:10.3390/ijms23073887
   Web of Science ®Google Scholar
• Badar T, Atallah E. Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes? Expert Opin Investig Drugs. 2021;30(6):665–673. doi:10.1080/13543784.2021.1915986
   PubMed Web of Science ®Google Scholar
• Keating GM. Azacitidine. Drugs. 2012;72(8):1111–1136. doi:10.2165/11209430-000000000-00000
   PubMed Web of Science ®Google Scholar
• Bernstein I, Byun HM, Mohrbacher A, et al. A Phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation. Epigenetics. 2010;5(8):750–757. doi:10.4161/epi.5.8.13105
   PubMed Web of Science ®Google Scholar
• Cruijsen M, Lübbert M, Wijermans P, Huls G. Clinical results of hypomethylating agents in AML treatment. J Clin Med. 2014;4(1):1–17. doi:10.3390/jcm4010001
   PubMed Web of Science ®Google Scholar
• Leone G, Teofili L, Voso MT, Lübbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002;87(12):1324–1341.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol. 2005;45(5):597–602. doi:10.1177/0091270004271947
   PubMed Web of Science ®Google Scholar
• Laille E, Goel S, Mita AC, et al. A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment. Pharmacotherapy. 2014;34(5):440–451. doi:10.1002/phar.1371
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895–3903. doi:10.1200/JCO.2005.05.4346
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JPJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer. 2006;106(8):1794–1803. doi:10.1002/cncr.21792
   PubMed Web of Science ®Google Scholar
• Schuh AC, Döhner H, Pleyer L, Seymour JF, Fenaux P, Dombret H. Azacitidine in adult patients with acute myeloid leukemia. Crit Rev Oncol Hematol. 2017;116:159–177. doi:10.1016/j.critrevonc.2017.05.010
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232. doi:10.1016/S1470-2045(09)70003-8
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299. doi:10.1182/blood-2015-01-621664
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–569. doi:10.1200/JCO.2009.23.8329
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Bally C, Thépot S, Quesnel B, et al. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Leuk Res. 2013;37(6):637–640. doi:10.1016/j.leukres.2013.02.014
   PubMed Web of Science ®Google Scholar
• Smith BD, Beach CL, Mahmoud D, Weber L, Henk HJ. Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. Exp Hematol Oncol. 2014;3(1):10. doi:10.1186/2162-3619-3-10
   PubMedGoogle Scholar
• Thépot S, Itzykson R, Seegers V, et al. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol. 2014;89(4):410–416. doi:10.1002/ajh.23654
   PubMed Web of Science ®Google Scholar
• Pleyer L, Burgstaller S, Girschikofsky M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol. 2014;93(11):1825–1838. doi:10.1007/s00277-014-2126-9
   PubMed Web of Science ®Google Scholar
• Ivanoff S, Gruson B, Chantepie SP, et al. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy. Am J Hematol. 2013;88(7):601–605. doi:10.1002/ajh.23464
   PubMed Web of Science ®Google Scholar
• Pleyer L, Döhner H, Dombret H, et al. Azacitidine for front-line therapy of patients with AML: reproducible efficacy established by direct comparison of international phase 3 trial data with registry data from the Austrian Azacitidine Registry of the AGMT study group. Int J Mol Sci. 2017;18:2. doi:10.3390/ijms18020415
   Web of Science ®Google Scholar
• Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer. 2012;118(4):1014–1022. doi:10.1002/cncr.26354
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thépot S, Berthon C, et al. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leuk Res. 2015;39(2):124–130. doi:10.1016/j.leukres.2014.11.009
   PubMed Web of Science ®Google Scholar
• de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370(Pt 3):737–749. doi:10.1042/bj20021321
   PubMed Web of Science ®Google Scholar
• Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1(4):287–299. doi:10.1038/nrd772
   PubMed Web of Science ®Google Scholar
• Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2’-deoxycytidine with valproic acid. Leuk Res. 2005;29(7):739–748. doi:10.1016/j.leukres.2004.11.022
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Abaza Y, Takahashi K, et al. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019;3(4):508–518. doi:10.1182/bloodadvances.2018027409
   PubMed Web of Science ®Google Scholar
• Badar T, Guru Murthy GS, Runaas L, et al. Phase I study of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory Acute Myeloid Leukemia (AML). Blood. 2019;134(Supplement_1):5068. doi:10.1182/blood-2019-123237
   Web of Science ®Google Scholar
• Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276(39):36734–36741. doi:10.1074/jbc.M101287200
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104(5):1266–1269. doi:10.1182/blood-2003-12-4333
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Knipp S, Fox F, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol. 2005;84(Suppl 1):61–66. doi:10.1007/s00277-005-0026-8
   PubMed Web of Science ®Google Scholar
• Adès L, Duployez N, Guerci-Bresler A, et al. A randomised Phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM’s “pick a winner” trial, with the impact of somatic mutations. Br J Haematol. 2022;198(3):535–544. doi:10.1111/bjh.18193
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Tallman MS, de Botton S, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019;33(11):2575–2584. doi:10.1038/s41375-019-0472-2
   PubMed Web of Science ®Google Scholar
• Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140:1845–1857. doi:10.1182/blood.2021014586
   PubMed Web of Science ®Google Scholar
• Sallman DA, Asch AS, Al Malki MM, et al. The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results. Blood. 2019;134(Supplement_1):569. doi:10.1182/blood-2019-126271
   Web of Science ®Google Scholar
• Wei AH, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383(26):2526–2537. doi:10.1056/NEJMoa2004444
   PubMed Web of Science ®Google Scholar
• Helsinn.com. Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis. Available from: https://helsinn.com/helsinn-group-and-mei-pharma-discontinue-the-phase-3-study-with-pracinostat-in-aml-after-completing-interim-analysis/. Accessed December 16, 2022.
   Google Scholar
• Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer. 2008;113(7):1596–1604. doi:10.1002/cncr.23789
   PubMed Web of Science ®Google Scholar
• Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. 2010;28(33):4919–4925. doi:10.1200/JCO.2010.30.3339
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Kohrt HE, Gallegos L, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2012;26(5):893–901. doi:10.1038/leu.2011.294
   PubMed Web of Science ®Google Scholar
• Narayan R, Garcia JS, Percival M-EM, et al. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leuk Lymphoma. 2016;57(3):609–615. doi:10.3109/10428194.2015.1091930
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375–388. doi:10.1016/j.ccr.2006.10.006
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117. doi:10.1158/2159-8290.CD-16-0313
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228. doi:10.1016/S1470-2045(18)30010-X
   PubMed Web of Science ®Google Scholar
• Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3(20):2911–2919. doi:10.1182/bloodadvances.2019000243
   PubMed Web of Science ®Google Scholar
• Cherry EM, Abbott D, Amaya M, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5(24):5565–5573. doi:10.1182/bloodadvances.2021005538
   PubMed Web of Science ®Google Scholar
• De Bellis E, Imbergamo S, Candoni A, et al. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience. Leuk Res. 2022;114:106803. doi:10.1016/j.leukres.2022.106803
   PubMed Web of Science ®Google Scholar
• Lindsay J, Teh BW, Micklethwaite K, Slavin M. Azole antifungals and new targeted therapies for hematological malignancy. Curr Opin Infect Dis. 2019;32(6):538–545. doi:10.1097/QCO.0000000000000611
   PubMed Web of Science ®Google Scholar
• Chang E, Ganguly S, Rajkhowa T, Gocke CD, Levis M, Konig H. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells. Leukemia. 2016;30(5):1025–1032. doi:10.1038/leu.2015.346
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3mutated AML. doi:10.1056/NEJMoa1902688
   Google Scholar
• Short NJ, DiNardo CD, Daver N, et al. A triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3mutated acute myeloid leukemia: results from a phase I/II study. doi:10.1182/blood-2021-153571
   Google Scholar
• Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519–1531. doi:10.1056/NEJMoa2117344
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398. doi: 10.1056/NEJMoa1716984
   PubMed Web of Science ®Google Scholar
• Badar T, Atallah E, Shallis RM, et al. Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022;97(7):E232–e5. doi:10.1002/ajh.26546
   PubMed Web of Science ®Google Scholar
• Cluzeau T, Sebert M, Rahmé R, et al. Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol. 2021;39(14):1575–1583. doi:10.1200/JCO.20.02342
   PubMed Web of Science ®Google Scholar
• Daver N, Vyas P, Chao M, et al. A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia. Blood. 2021;138:3426. doi:10.1182/blood-2021-145208
   Web of Science ®Google Scholar
• Döhner H, Wei AH, Roboz GJ, et al. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood. 2022;140(15):1674–1685. doi:10.1182/blood.2022016293
   PubMed Web of Science ®Google Scholar